Launch
First siRNA Therapy Approved for Myasthenia Gravis
The Brief
- The FDA approved subcutaneous cemdisiran, branded Livsayis, for generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody-positive.
- Cemdisiran is a small interfering RNA (siRNA) therapy, the first siRNA treatment approved for myasthenia gravis according to the headline.
- The approval was announced by Regeneron.
Why it matters
It establishes siRNA, a gene-silencing approach, as a clinically approved option for an autoimmune neuromuscular disease, which may matter for other antibody-mediated conditions being studied with similar therapies.
Who’s affected
- adults with generalized myasthenia gravis who are AChR antibody-positive
- neurologists and other clinicians treating myasthenia gravis
(MedPage Today) -- The FDA approved subcutaneous cemdisiran (Livsayis), a small interfering RNA (siRNA) therapy, to treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody-positive, Regeneron announced...